Home » FDA Grants Orphan Drug Designation for Corneal Cross-Linking Treatment for Keratoconus
FDA Grants Orphan Drug Designation for Corneal Cross-Linking Treatment for Keratoconus
September 13, 2011
The U.S. Food and Drug Administration has granted orphan drug status to Avedro for a riboflavin ophthalmic solution combined with a corneal cross-linking system to test keratoconus.
OSN Super Site
OSN Super Site
Upcoming Events
-
21Oct